Revolution Medicines, Inc. (RVMD)
Market Cap | 2.28B |
Revenue (ttm) | 35.38M |
Net Income (ttm) | -248.71M |
Shares Out | 106.17M |
EPS (ttm) | -3.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 506,527 |
Open | 21.61 |
Previous Close | 21.52 |
Day's Range | 21.11 - 22.19 |
52-Week Range | 14.08 - 31.37 |
Beta | 1.49 |
Analysts | Buy |
Price Target | 32.51 (+51.35%) |
Earnings Date | May 8, 2023 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the... [Read more]
Financial Performance
In 2022, RVMD's revenue was $35.38 million, an increase of 20.38% compared to the previous year's $29.39 million. Losses were -$248.71 million, 32.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $32.51, which is an increase of 51.35% from the latest price.
News

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $345.0 million Underwriters' full exercise of option brings gross proceeds to $345.0 million

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

Revolution Medicines Announces Commencement of Public Offering of Common Stock
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today anno...

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s...

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice
Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st...

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Ke...

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi's Termination of SHP2 Inhibitor Development and Commercialization Collaboration
Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combinatio...

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor
KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is quest...

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
First two RAS(ON) Inhibitor drug candidates advance into clinical development

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $264.5 million Underwriters' full exercise of option brings gross proceeds to $264.5 million

Revolution Medicines Stock Is Getting Hammered: Here's Why
Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares ...

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
Board composition evolves as company's development pipeline matures Board composition evolves as company's development pipeline matures

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations